| Recruiting | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment NCT04919629 | Roswell Park Cancer Institute | Phase 2 |
| Unknown | AMT-151 in Patients With Selected Advanced Solid Tumours NCT05498597 | Multitude Therapeutics Inc. | Phase 1 |
| Active Not Recruiting | Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage NCT05276973 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Tr NCT05415709 | Ohio State University Comprehensive Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Ca NCT05226507 | Nuvectis Pharma, Inc. | Phase 1 |
| Withdrawn | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers NCT04611139 | HonorHealth Research Institute | Phase 1 |
| Terminated | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal NCT03924245 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Recruiting | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary NCT04575935 | M.D. Anderson Cancer Center | Phase 3 |
| Terminated | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors NCT03641287 | University of Washington | N/A |
| Active Not Recruiting | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube NCT03587311 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (o NCT03648489 | Imperial College London | Phase 2 |
| Terminated | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, F NCT02923739 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, NCT02713386 | NRG Oncology | Phase 1 / Phase 2 |
| Completed | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, NCT02853318 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Re NCT02502266 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Terminated | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cance NCT02364713 | Mayo Clinic | Phase 2 |
| Completed | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritone NCT02122185 | University of Chicago | Phase 2 |
| Completed | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube NCT02283658 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, NCT02101775 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid T NCT02142803 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Can NCT02068794 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavi NCT02111941 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707 | Mayo Clinic | Phase 1 |
| Completed | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent O NCT01489371 | Gynecologic Oncology Group | Phase 1 |
| Unknown | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previo NCT00719303 | Gynecologic Oncology Group | Phase 3 |
| Withdrawn | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithe NCT01492920 | Gynecologic Oncology Group | Phase 3 |
| Completed | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian NCT01504126 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients Wi NCT01459380 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherap NCT01275664 | Gynecologic Oncology Group | N/A |
| Completed | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients Wit NCT01294293 | Gynecologic Oncology Group | Phase 1 |
| Completed | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, NCT00888615 | GOG Foundation | Phase 2 |
| Active Not Recruiting | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage NCT01167712 | National Cancer Institute (NCI) | Phase 3 |
| Completed | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ov NCT01097746 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Canc NCT01116648 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelia NCT01074411 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritone NCT01080521 | Gynecologic Oncology Group | — |
| Completed | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallop NCT00993616 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovar NCT00989651 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Isl NCT01010126 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epi NCT00951496 | National Cancer Institute (NCI) | Phase 3 |
| Completed | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Prim NCT00939809 | Gynecologic Oncology Group | Phase 2 |
| Active Not Recruiting | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Pa NCT00565851 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ova NCT00466960 | University of Washington | Phase 2 |
| Completed | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian NCT00262847 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carc NCT00357448 | University of Washington | Phase 1 |
| Unknown | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian E NCT00108745 | GOG Foundation | Phase 3 |
| Completed | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulkin NCT00079430 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in T NCT00085358 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopia NCT00060359 | Gynecologic Oncology Group | Phase 1 |
| Completed | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma NCT00059787 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian NCT00004221 | Gynecologic Oncology Group | Phase 2 |
| Completed | Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stag NCT00002913 | National Cancer Institute (NCI) | Phase 1 |